Zydus Cadila, an innovation-driven global pharmaceutical company, has settled the patent litigation relating to Allergan’s DELZICOL (mesalamine). As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL in the United States beginning on March 1, 2020, or earlier under certain circumstances.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
